ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Omeros Corporation

Omeros Corporation (OMER)

3.06
0.02
(0.66%)
Closed April 26 4:00PM
3.06
0.00
(0.00%)
After Hours: 4:00PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
3.06
Bid
2.96
Ask
3.27
Volume
255,397
2.965 Day's Range 3.10
0.92 52 Week Range 7.7975
Market Cap
Previous Close
3.04
Open
3.01
Last Trade Time
Financial Volume
$ 771,396
VWAP
3.0204
Average Volume (3m)
493,110
Shares Outstanding
62,865,491
Dividend Yield
-
PE Ratio
-1.63
Earnings Per Share (EPS)
-1.87
Revenue
-
Net Profit
-117.81M

About Omeros Corporation

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injec... Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Tumwater, Washington, USA
Founded
1970
Omeros Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker OMER. The last closing price for Omeros was $3.04. Over the last year, Omeros shares have traded in a share price range of $ 0.92 to $ 7.7975.

Omeros currently has 62,865,491 shares outstanding. The market capitalization of Omeros is $191.74 million. Omeros has a price to earnings ratio (PE ratio) of -1.63.

OMER Latest News

Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results

– Conference Call Today at 4:30 p.m. ET Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and...

Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023, on Monday, April 1, 2024, after the market...

Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated...

Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust

– Expands DRI royalty deal on U.S. net sales of OMIDRIA – – Expanded deal brings Omeros $115 million upfront payment and opportunity for additional $55 million in sales-based milestones – Omeros...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.26-7.83132530123.323.412.9653125273.1033708CS
4-0.43-12.32091690543.494.12.8394021183.32343492CS
12-0.49-13.80281690143.555.1352.8394931103.88424137CS
261.79140.944881891.275.1351.056175243.08803815CS
52-3.02-49.67105263166.087.79750.926365213.70837317CS
156-15.59-83.592493297618.6518.860.927807145.65781028CS
260-15.84-83.809523809518.925.490.927475889.28181725CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ISUNiSun Inc
$ 0.173
(84.04%)
19.85M
BRFHBarfresh Food Group Inc
$ 1.75
(69.90%)
41.45M
SGBXSafe and Green Holdings Corporation
$ 0.225
(56.14%)
132.51M
PCSAProcessa Pharmaceuticals Inc
$ 2.4137
(48.99%)
69.6M
BACKIMAC Holdings Inc
$ 5.065
(45.34%)
8.49M
EJHE Home Household Service Holdings Ltd
$ 0.767
(-73.64%)
12.36M
TVGNTevogen Bio Holdings Inc
$ 0.9057
(-39.62%)
328.69k
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.265
(-37.69%)
16.75M
ATNIATN International Inc
$ 19.24
(-33.01%)
440.2k
BNAIBrand Engagement Network Inc
$ 2.59
(-30.56%)
234.29k
SQQQProShares UltraPro Short QQQ
$ 12.00
(1.61%)
167.48M
SGBXSafe and Green Holdings Corporation
$ 0.225
(56.14%)
136.91M
TSLATesla Inc
$ 170.18
(4.97%)
126.42M
ACONAclarion Inc
$ 0.383149
(33.04%)
115.53M
TQQQProShares UltraPro QQQ
$ 52.85
(-1.60%)
86.41M

OMER Discussion

View Posts
Monksdream Monksdream 6 months ago
OMER new 52=week low
Then bounce
👍️0
shurtha2000 shurtha2000 6 months ago
$341M cash and $12M recievables
👍️0
starkd748 starkd748 1 year ago
Gap filled 6s 7s next top
👍️0
Roadtojourney Roadtojourney 1 year ago
With the type of news this should have been above 5 not sure whats wrong here?
👍️0
starkd748 starkd748 1 year ago
3.20 gap must fill now
👍️0
TheFinalCD TheFinalCD 1 year ago
OMER $200M PAYMENT
👍️0
makinezmoney makinezmoney 1 year ago
$OMER: She back on fire now............ sheeeshhhhhhhhhhhhhh


Go baby goooooooooo.......... $3 breaker upside




GO $OMER
👍️0
starkd748 starkd748 2 years ago
Weeeeeeee
👍️0
starkd748 starkd748 2 years ago
We get some 5s I'm backing up the truck
👍️0
starkd748 starkd748 2 years ago
Was a good trade but it's been done since 7s
👍️0
starkd748 starkd748 2 years ago
Weeeeee
👍️0
starkd748 starkd748 2 years ago
Weeeeeeeeeeeee
👍️0
starkd748 starkd748 2 years ago
Yesss
👍️0
starkd748 starkd748 2 years ago
Looking good
👍️0
starkd748 starkd748 2 years ago
Weeeeee
👍️0
starkd748 starkd748 2 years ago
Yesss
👍️0
starkd748 starkd748 2 years ago
Bounced off the low 3s time to load
👍️0
starkd748 starkd748 2 years ago
Maybe an A B C ... 2.17 might coming
👍️0
starkd748 starkd748 2 years ago
Not ready yet
👍️0
starkd748 starkd748 2 years ago
I like this at a certain fib level hehehe
👍️0
bandit007 bandit007 2 years ago
Great day here! $OMER
👍️0
bandit007 bandit007 2 years ago
Breaking out!
👍️0
bandit007 bandit007 2 years ago
Looking good here. Steady climb
👍️0
bandit007 bandit007 2 years ago
Looking good here. Steady climb
👍️0
Scott 75 Scott 75 2 years ago
Wow! Thanks for sharing. I can't believe with all that going for it and the price is so beaten down.
👍️0
Nefyn Nefyn 2 years ago
So what happens to OMER…a public company with tons of cash and no business operations?
👍️0
JackAskSlap JackAskSlap 2 years ago
Bahhh Bahhh

gonna do this all day long
👍️0
JackAskSlap JackAskSlap 2 years ago
another round for the apes Lets GO !!
👍️0
JackAskSlap JackAskSlap 2 years ago
Glad I'm just a robot no emotions needed
👍️0
JackAskSlap JackAskSlap 2 years ago
Fk with BB My new addiction
👍️0
JackAskSlap JackAskSlap 2 years ago
IN now I'm gonna tick flip this POS to death
👍️0
JackAskSlap JackAskSlap 2 years ago
Trying for the baseline
no holds barred..
👍️0
Jess070283 Jess070283 2 years ago
Load it up!$$$
👍️0
TheGreenReaper TheGreenReaper 2 years ago
OMER$$$$
👍️0
Golden Cross Golden Cross 2 years ago
$14 Targeting
👍️0
crudeoil24 crudeoil24 2 years ago
59M trading float. Huge news out >
👍️0
crudeoil24 crudeoil24 2 years ago
Shorts feeling the heat!!!!! >
👍️0
crudeoil24 crudeoil24 2 years ago
>>>>> GANGBUSTERS <<<<< $$$$$

OMER
👍️0
crudeoil24 crudeoil24 2 years ago
OMER > That is a sweet revenue deal. OMER heading to $20.00+
$125 million upfront payment and $200 million on achievement of commercial milestone
Royalties of 50% on U.S. net sales until the earlier of either January 1, 2025 or payment of the $200-million milestone, after which royalties adjust to 30% of U.S. net sales
Royalties of 15% on ex-U.S. net sales
OMIDRIA to become a premier product in Rayner’s ophthalmology franchise
In addition to acquiring the OMIDRIA commercial organization, including the current OMIDRIA sales force, Rayner plans to further expand its U.S. and ex-U.S. sales forces
👍️0
TheFinalCD TheFinalCD 2 years ago
https://ih.advfn.com/stock-market/NASDAQ/omeros-OMER/stock-news/86711139/omeros-announces-agreement-to-sell-omidria-franch
👍️0
Frankestin Frankestin 3 years ago
Here are the 5!
Very interesting if it goes under!
I would be tempted to open the position now!
👍️0
Frankestin Frankestin 3 years ago
Someone says 5 ... will it get there?
I would like to enter but of course they spend a lot on research and development... and for sell
👍️0
Frankestin Frankestin 3 years ago
ooOOoo
I take a handful these days!
👍️0
Termite7 Termite7 3 years ago
Buying opportunity???
👍️0
frugalNorwegian frugalNorwegian 3 years ago
I created a page on my site talking about OMER. Let me know if I am missing any nuggets. Thanks.

https://frugalnorwegian.com/omer

Summary: This company is a prime candidate for a buyout if FDA approval is given.
👍️0
Dr_Thorfin Dr_Thorfin 3 years ago
If one is worried about fda's delay, Check out @alanrobertross message on StockTwits http://stocktwits.com/alanrobertross/message/333077805
👍️0
umiak umiak 3 years ago
Tute ownership up to 78% been hovering around 50% for years. 20% short
👍️0
umiak umiak 3 years ago
Not new news but I like the smart reporting style:
Omeros's Biologics License Application for Blood Vessel Damage Treatment Candidate Accepted for Priority Review by FDA

1/19/21, 8:06 AM
10:06 AM EST, 01/19/2021 (MT Newswires) -- Omeros (OMER) said Tuesday its biologics license application for narsoplimab, a potential treatment for transplant-associated thrombotic microangiopathy, has been accepted for priority review by the US Food and Drug Administration.

Thrombotic microangiopathy is characterized by a pattern of damage in the small blood vessels.

The FDA has set the Prescription Drug User Fee Act action date on July 17.
👍️0
umiak umiak 3 years ago
Have you looked at NLST? Short story:

*google signed a NDA with NLST to use their seminal technology
*google was bad even lied to court
*they lost their appeal
*google let date to file with scotus pass
*now one way or another they must pay
*one way to pay--google's case and settlement with ADT(eye opening)
*another way to pay-- Centripetal v Cisco (cisco was bad for 3 yrs
google is on the hook for 11 yrs)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160597164
*estimate to file to lift stay Q1 2021
*bought dips as low as .48 keep adding
*yahoo board and ihub board are bullish
lots of speculation but also good info.
*there are active cases with other companies Sk-hynic recently lost
on 2 parts of patent 907
*scheduled markman for infringement of (NLST)patents 218 and 595 3/9/2021
trial, if defendants choose, 12/2021
*it is a popping year for NLST they have been chasing google in court for 11 yrs, google will have to settle.
👍️0
umiak umiak 3 years ago
👍️0

Your Recent History

Delayed Upgrade Clock